Medical Device Regulation in Thailand

TL;DR

Medical devices in Thailand are regulated under the Medical Device Act B.E. 2551 (2008), substantially amended in 2019 to align with the ASEAN Medical Device Directive (AMDD). The FDA-Thai Medical Device Control Division administers. Devices are classified into four risk classes (1, 2, 3, 4). Pre-market obligations include notification (Class 1) or registration (Classes 2-4); post-market includes adverse-event reporting.

Risk Classes

Registration Path

1. Classify device per AMDD rules.
2. Compile Common Submission Dossier Template (CSDT).
3. QMS evidence (ISO 13485 commonly accepted).
4. Clinical evaluation report.
5. FDA-Thai review (timeline by class).
6. Licence issued; renewable per term.

Post-Market Obligations

• Adverse-event reporting (15 / 30 / 90 day windows by severity).
• Field-safety corrective actions.
• Re-registration on major change.
• Annual reports for Class 3 / 4.

Common Mistakes

• Misclassifying borderline products (e.g., wellness apps that meet medical-device definition).
• Using foreign clinical data without bridging study.
• Skipping QMS evidence.

FAQs

1. Software-as-a-medical-device (SaMD)?

Yes — SaMD is regulated; classification per intended use.

Risk-Based Classification

Medical devices are regulated by the Thai FDA under the Medical Device Act B.E. 2551 (2008), as amended by the Act of B.E. 2562 (2019). The regime is risk-based, with devices grouped into classes from low risk (Class 1) to high risk (Class 4) based on intended use and the potential harm from failure. The class determines the control pathway — broadly, higher-risk devices require full licensing/registration before marketing, medium-risk devices a notification, and the lowest-risk devices a listing. Software intended for a medical purpose (SaMD) is treated as a device and classified by its intended use.

What Manufacturers and Importers Must Do

A person who manufactures or imports devices needs the appropriate establishment licence and must place a registered/notified/listed product on the market, supported by evidence of safety and performance and a quality management system (QMS). Foreign clinical or technical data can often be relied on, but sponsors should confirm whether local bridging evidence is expected for the specific device. Post-market obligations include adverse-event reporting, labelling in line with the rules, and controls on advertising. Common pitfalls are marketing before registration is complete, misclassifying a device to a lower class, and thin QMS documentation.

2. Are in-vitro diagnostics (IVDs) covered?

Yes — IVDs are medical devices and are classified and controlled under the same Act, with the pathway depending on the risk associated with an incorrect result.

Related Reading

• Pharmaceutical Regulation
• Health & Medical Law Hub